Werewolf Competitors

HOWL Stock  USD 1.20  0.01  0.83%   
Werewolf Therapeutics competes with Monte Rosa, Design Therapeutics, Ikena Oncology, Stoke Therapeutics, and Edgewise Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Werewolf Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Werewolf Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Werewolf Therapeutics Correlation with its peers.
For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Werewolf Therapeutics competition on your existing holdings.
  
The value of Return On Tangible Assets is estimated to slide to -0.58. The value of Return On Capital Employed is expected to slide to -0.69. At this time, Werewolf Therapeutics' Total Assets are quite stable compared to the past year. Net Tangible Assets is expected to rise to about 147.7 M this year, although the value of Other Assets will most likely fall to 1.09.
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Werewolf Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.061.205.29
Details
Intrinsic
Valuation
LowRealHigh
0.193.877.96
Details
6 Analysts
Consensus
LowTargetHigh
10.9212.0013.32
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.43-0.42-0.42
Details

Werewolf Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Werewolf Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Werewolf and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Werewolf Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
CCCCIKNA
CCCCSTOK
STOKGLUE
STOKIKNA
EWTXSTOK
CELCSTOK
  
High negative correlations   
ACETTALS
TALSCCCC
TALSCELC
ACETDBTX
TALSDBTX
CCCCDBTX

Risk-Adjusted Indicators

There is a big difference between Werewolf Stock performing well and Werewolf Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Werewolf Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
GLUE  3.71 (0.28) 0.00 (0.39) 0.00 
 7.68 
 19.92 
DSGN  4.49 (0.15) 0.00 (0.40) 0.00 
 9.45 
 26.51 
IKNA  1.96 (0.23) 0.00 (0.60) 0.00 
 4.65 
 16.13 
STOK  3.44 (0.36) 0.00 (0.39) 0.00 
 7.03 
 21.09 
EWTX  3.00 (0.04) 0.00 (0.17) 0.00 
 5.32 
 26.44 
DBTX  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
CELC  3.07 (0.18) 0.00 (0.42) 0.00 
 6.28 
 21.63 
CCCC  3.77 (0.54) 0.00 (0.36) 0.00 
 7.35 
 24.77 
TALS  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
ACET  3.30 (0.13) 0.00 (0.27) 0.00 
 6.67 
 20.19 

Cross Equities Net Income Analysis

Compare Werewolf Therapeutics and related stocks such as Monte Rosa Therapeutics, Design Therapeutics, and Ikena Oncology Net Income Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D AShort Term Coverage Ratios
Price Earnings RatioOperating Cycle
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Cash Conversion CycleOperating Cash Flow Sales Ratio
Days Of Inventory OutstandingDays Of Sales Outstanding
Free Cash Flow Operating Cash Flow RatioCash Flow Coverage Ratios
Price To Book RatioFixed Asset Turnover
Capital Expenditure Coverage RatioPrice Cash Flow Ratio
Enterprise Value MultipleDebt Ratio
Cash Flow To Debt RatioPrice Sales Ratio
Return On AssetsAsset Turnover
Net Profit MarginGross Profit Margin
Price Fair ValueReturn On Equity
2010201120122013201420152016201720182019202020212022202320242025
GLUE(8 M)(8 M)(8 M)(8 M)(8 M)(8 M)(8 M)(8 M)(8 M)(8 M)(36.1 M)(71.9 M)(104.6 M)(135.4 M)(121.8 M)(115.7 M)
DSGN(2 M)(2 M)(2 M)(2 M)(2 M)(2 M)(2 M)(2 M)(2 M)(2 M)(8.3 M)(35.5 M)(58.6 M)(66.9 M)(49.6 M)(52.1 M)
IKNA(16.8 M)(16.8 M)(16.8 M)(16.8 M)(16.8 M)(16.8 M)(16.8 M)(16.8 M)(16.8 M)(16.8 M)(44.3 M)(34.1 M)(66.6 M)(68.2 M)(49.2 M)(51.7 M)
STOK(5.6 M)(5.6 M)(5.6 M)(5.6 M)(5.6 M)(5.6 M)(5.6 M)(5.6 M)(12.5 M)(28.5 M)(50.6 M)(84.7 M)(93.1 M)(104.7 M)(94.2 M)(89.5 M)
EWTX(9.5 M)(9.5 M)(9.5 M)(9.5 M)(9.5 M)(9.5 M)(9.5 M)(9.5 M)(9.5 M)(9.5 M)(17.1 M)(42.1 M)(15.4 M)(100.2 M)(133.8 M)(127.1 M)
CELC(2.3 M)(2.3 M)(2.3 M)(2.3 M)(2.3 M)(2.3 M)(3.3 M)(6.3 M)(7.5 M)(7 M)(9.1 M)(30.6 M)(41.3 M)(63.8 M)(57.4 M)(54.5 M)
CCCC(15.7 M)(15.7 M)(15.7 M)(15.7 M)(15.7 M)(15.7 M)(15.7 M)(15.7 M)(15.7 M)(34.1 M)(66.3 M)(86 M)(126.5 M)(132.5 M)(105.3 M)(110.6 M)
ACET13.5 MM17 M22.3 M22.3 M29 M(1000)(33.8 M)(9.3 M)(28.1 M)(36.7 M)(62 M)(67 M)(142.7 M)(117.1 M)(111.3 M)
CGEM(704.7 K)(704.7 K)(704.7 K)(704.7 K)(130.5 K)(109.5 K)(316.7 K)(14.2 M)(14.2 M)(20 M)(50.8 M)(65 M)111.2 M(153.2 M)(167.4 M)(159 M)
VOR(4.2 M)(4.2 M)(4.2 M)(4.2 M)(4.2 M)(4.2 M)(4.2 M)(4.2 M)(4.2 M)(11.4 M)(43.3 M)(68.8 M)(90.8 M)(117.9 M)(106.1 M)(100.8 M)
THRD(12.8 M)(12.8 M)(12.8 M)(12.8 M)(12.8 M)(12.8 M)(12.8 M)(12.8 M)(12.8 M)(12.8 M)(12.8 M)(29.6 M)(37.7 M)(30.8 M)(27.7 M)(29.1 M)
PASG(12.8 M)(12.8 M)(12.8 M)(12.8 M)(12.8 M)(12.8 M)(12.8 M)(12.8 M)(12.8 M)(54.6 M)(111.8 M)(191.5 M)(136.9 M)(102.1 M)(64.8 M)(68 M)
ACRV(5.3 M)(5.3 M)(5.3 M)(5.3 M)(5.3 M)(5.3 M)(5.3 M)(5.3 M)(5.3 M)(5.3 M)(5.3 M)(16.2 M)(29.7 M)(60.4 M)(54.3 M)(51.6 M)
MOLN7.1 M7.1 M7.1 M7.1 M(2.3 M)(148.8 K)(18.6 M)(25.4 M)(37 M)(36.3 M)(62.8 M)(63.8 M)117.9 M(62 M)(54 M)(51.3 M)
MNOV(1.8 M)(17.7 M)(11 M)(4 M)(9.2 M)(8.8 M)(10.9 M)(11.2 M)(14.7 M)(12.9 M)(13.9 M)(10.1 M)(14.1 M)(8.6 M)(11 M)(11.6 M)
ANEB(174.6 K)(174.6 K)(174.6 K)(174.6 K)(174.6 K)(174.6 K)(174.6 K)(174.6 K)(174.6 K)(174.6 K)(30.3 M)(6.8 M)(11.7 M)(8.2 M)(9.4 M)(9.9 M)
CSBR50 K(8.7 M)(6.4 M)(7.4 M)(13.1 M)(10.4 M)(6.9 M)(1.5 M)128 K(2 M)362 K548 K(5.3 M)(7.3 M)(6.5 M)(6.2 M)

Werewolf Therapeutics and related stocks such as Monte Rosa Therapeutics, Design Therapeutics, and Ikena Oncology Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Werewolf Therapeutics financial statement analysis. It represents the amount of money remaining after all of Werewolf Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Werewolf Therapeutics Competitive Analysis

The better you understand Werewolf Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Werewolf Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Werewolf Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
HOWL GLUE DSGN IKNA STOK EWTX CELC CCCC ACET CGEM
 0.83 
 1.20 
Werewolf
 0.97 
 6.27 
Monte
 0.21 
 4.71 
Design
 1.47 
 1.34 
Ikena
 6.04 
 8.60 
Stoke
 1.54 
 25.67 
Edgewise
 7.81 
 10.03 
Celcuity
 0.50 
 2.03 
CCCC
 1.27 
 0.78 
Adicet
 1.46 
 8.79 
Cullinan
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Trade Advice
(90 Days Macroaxis Advice)
Current Ratio
Net Asset
Profit Margin
EBITDA
Operating Margin
Current Valuation
Price To Book
Retained Earnings
Current Asset
Five Year Return
Beta
Number Of Employees
Shares Outstanding
Cash Flow From Operations
Total Debt
Return On Equity
Z Score
Return On Asset
Number Of Shares Shorted
Book Value Per Share
Current Liabilities
Total Asset
Debt To Equity
Short Ratio
Target Price
Shares Owned By Institutions
Market Capitalization
Price To Earning
Price To Earnings To Growth
Price To Sales
Net Income
Earnings Per Share
Shares Owned By Insiders
Revenue
Working Capital
Cash And Equivalents
Cash Per Share
Gross Profit
Day Typical Price
Accumulation Distribution
Market Facilitation Index
Daily Balance Of Power
Period Momentum Indicator
Rate Of Daily Change
Day Median Price
Price Action Indicator
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Werewolf Therapeutics Competition Performance Charts

Five steps to successful analysis of Werewolf Therapeutics Competition

Werewolf Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Werewolf Therapeutics in relation to its competition. Werewolf Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Werewolf Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Werewolf Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Werewolf Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Werewolf Therapeutics position

In addition to having Werewolf Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Defense Thematic Idea Now

Defense
Defense Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Defense theme has 15 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Defense Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Werewolf Therapeutics is a strong investment it is important to analyze Werewolf Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Werewolf Therapeutics' future performance. For an informed investment choice regarding Werewolf Stock, refer to the following important reports:
Check out Werewolf Therapeutics Correlation with its peers.
For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.63)
Revenue Per Share
0.044
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.30)
Return On Equity
(0.76)
The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.